Interleukin-17 antagonists in the treatment of psoriasis.

Abstract

BACKGROUND:

Psoriasis is a chronic, immune-mediated inflammatory skin disorder of unknown etiology. Interleukin (IL)-17a, a key product of the recently identified Th17 cell subset, has been found to play a critical role in the immunopathogenesis of psoriasis. IL-17 antagonists are a new class of biological agent currently in development for psoriasis that selectively inhibit IL-17a activity.

OBJECTIVE:

This review aims to summarize the current efficacy data from phase II randomized controlled trials of the IL-17 antagonists brodalumab, ixekizumab, and secukinumab for the treatment of moderate to severe psoriasis.

CONCLUSION:

Patients treated with IL-17 antagonists achieved marked reduction in psoriasis disease severity as demonstrated by the Psoriasis Area and Severity Index (PASI) 75 response rates. A sizable proportion of patients treated with brodalumab and ixekizumab achieved unprecedented clinical clearance of their psoriasis (PASI > 90). These encouraging results demonstrate the efficacy of these agents and validate the pro-inflammatory role of IL-17 in the pathophysiology of psoriasis.

• Authors: Shivani Felicia Chandrakumar, Jensen Yeung
• Journal: Journal of cutaneous medicine and surgery (J Cutan Med Surg) 2015 Mar-Apr Vol. 19 Issue 2 Pg. 109-14 ISSN: 1203-4754 [Print] United States
• PMID: 25775627 (Publication Type: Journal Article, Review)
• Copyright: © 2014 Canadian Dermatology Association.

Chemical References

• Biological Factors
• Interleukin-17

Topics

• Biological Factors (therapeutic use)
• Humans
• Interleukin-17 (antagonists & inhibitors)
• Psoriasis (drug therapy, pathology)
• Skin (pathology)
• Treatment Outcome